Zanubrutinib, sold under the brand name Brukinsa, is an anticancer medication used for the treatment of mantle cell lymphoma, Waldenström's macroglobulinemia, marginal zone lymphoma, and chronic lymphocytic leukemia. Zanubrutinib is classified as a Bruton tyrosine kinase inhibitor that irreversibly alkylates the Cys481 residue in the BTK active site, producing sustained BTK occupancy and downstream inhibition of B cell receptor signaling; it is an orally available small molecule developed for improved BTK selectivity compared with first generation agents, is typically dosed as 160 mg twice daily or 320 mg once daily depending on indication, is metabolized predominantly by CYP3A enzymes with clinically relevant drug interaction potential, and requires monitoring for hematologic toxicity, bleeding risk, infections, and atrial arrhythmias as part of routine clinical management.
![4-Nitroso-2-(4-phenoxyphenyl)-7-(piperidin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carbonitrile](https://veeprho.com/wp-content/uploads/2025/06/VE0024202-4-nitroso-2-4-phenoxyphenyl-7.png "4-Nitroso-2-(4-phenoxyphenyl)-7-(piperidin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carbonitrile")
Parent: Zanubrutinib
Typical quality specifications established during development and registration for zanubrutinib API and finished drug substance limit individual known related compounds to the low single digit tenths of a percent range and total impurities to under one percent by area percent; in practice this is commonly expressed as individual identified impurities at or below 0.10 to 0.20 percent (1000 to 2000 ppm), unspecified impurities below 0.05 percent (500 ppm), and total impurities below 1.0 percent (10 000 ppm), with tighter limits applied for genotoxic impurities following ICH M7 guidance and qualification thresholds set by safety assessment; related substances characterized during stability and forced-degradation studies include morpholine N-oxide species, mono-oxidation products, dealkylated and demethylated variants, and hydrolytic degradants, and release and stability testing employs validated stability-indicating HPLC and LC-MS methods to quantify these impurities and ensure conformance to specification.
No, Zanubrutinib is a targeted small-molecule inhibitor of Bruton tyrosine kinase and is classified as targeted therapy rather than conventional cytotoxic chemotherapy, though it can produce myelosuppression and other systemic effects similar to cytotoxic agents.
The most commonly reported clinically significant adverse effect is neutropenia among hematologic toxicities; common nonhematologic effects include upper respiratory tract infection, diarrhea, and bruising or bleeding tendencies.
Cost varies by country, dosing, pharmacy and insurance coverage; in the United States the brand product list-price estimates range roughly from about USD 12 000 to USD 20 000 per month for typical dosing, but patient out of pocket costs are often much lower with insurance, assistance programs, or negotiated pricing.
Success is usually reported as overall response rate and durability of response and varies by indication and prior therapy; pivotal and registration studies have reported overall response rates generally in the range of about 70 percent to over 90 percent depending on disease context, with high proportions of durable responses in many patients and improved tolerability versus some earlier BTK inhibitors.
